Page 39 - Peptide News Today

Les peptides qui causent la douleur migraineuse pourraient influencer la production dinsuline en régulant la quantité dinsuline sécrétée ou en augmentant le nombre de cellules pancréatiques qui la produisent, protégeant ainsi du développement d’un diabète de type 2.

Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates

Chemikern der Universität Göttingen ist es gelungen, die in biologischen Systemen und Arzneimitteln besonders aktive Struktur der Chromone in nur einem Schritt herzustellen – ausgehend von günstig ...

Hits: 239 BAGSVAERD, Denmark I May 28, 2021 I Novo Nordisk today announced the resubmission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic ®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. The resubmission follows the Refusal to File letter received by the FDA on 22 March 2021. The standard review time by the FDA is 10 months. About Novo Nordisk Novo Nordisk is a...

The two early intervention drugs target how human cells respond to the SARS-CoV-2 virus, instead of the virus itself, according to the findings published in the journal Nature Cell Discovery.The

The two early intervention drugs target how human cells respond to the SARS-CoV-2 virus, instead of the virus itself, according to the findings published in the journal Nature Cell Discovery.The

Hits: 447 Treatment naïve Switching from C5 inhibitor Ultomiris® (ravulizumab) EMPAVELI was superior to Soliris for the change from baseline in hemoglobin level at Week 16 in the Phase 3 PEGASUS study 85% of patients treated with EMPAVELI were transfusion free compared to 15% on Soliris at Week 16; EMPAVELI met non-inferiority compared to Soliris on transfusion avoidance WALTHAM, MA, USA I May 14, 2021 I Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company an...

Hits: 92 · No unexpected safety findings and no relevant safety differences between zilucoplan and placebo were identified · Phase 3 headline results for generalized myasthenia gravis (gMG) are unchanged expected in Q4 2021 BRUSSELS, Belgium I April 22, 2021 I Based on the initial results of a Phase 2 study investigating zilucoplan in immune-mediated necrotizing myopathy (IMNM), UCB today announced that UCB has decided to not move forward with its IMNM development program.  The phase...

Hits: 137 GAITHERSBURG, MD, USA and GUANGZHOU, China I April 21, 2021 I RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today execution of definitive agreements for a seed round financing of $10 million. RNAimmune is a spin-off entity from Sirnaomics, a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases. Smooth River and Hong Kon...

Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026 Report Highlights: First FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide) Pepaxto Clinical and Commercial Insight: Dosage, Patent, Price, Sales Forecast Peptide Drug Conjugate Sales Opportunity: US, Europe, Japan and South Korea Global Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs Clinical Trials Insight by Company, Country, Indication Patent Insight of Peptide Drug Conjugates Profile and Clinical P...